Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dorzolamide + timolol is a fixed-dose combination of two active pharmaceutical ingredients, dorzolamide hydrochloride (a carbonic anhydrase inhibitor) and timolol maleate (a non-selective beta-adrenergic receptor blocker), formulated as an ophthalmic solution. It is used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers alone. Dorzolamide decreases aqueous humor secretion by inhibiting carbonic anhydrase II in the ciliary processes, reducing bicarbonate ion formation and subsequent fluid transport. Timolol reduces aqueous humor production by blocking beta-adrenergic receptors in the eye. The combination provides additive effects for lowering intraocular pressure, thereby reducing the risk of optic nerve damage and glaucomatous visual field loss[1][2][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dorzolamide + timolol.